|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 31/40 | |
| A61K 9/22 | |||
| A61K 9/24 |
| (11) | Patento numeris | 2191824 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 09172285.0 |
| Europos patento paraiškos padavimo data | 2006-06-08 | |
| (97) | Europos patento paraiškos paskelbimo data | 2010-06-02 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2012-03-14 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (30) | Numeris | Data | Šalis |
| 689719 P | 2005-06-10 | US | |
| 690309 P | 2005-06-14 | US |
| (72) |
Kowalski, James, US
Lakshman, Jay, Parthiban, US
Serajuddin, Abu, T. M., US
Joshi, Yatindra, US
|
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
Novartis Pharma GmbH, Brunner Strasse 59, 1230 Wien, AT |
| (54) | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
| Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |